What are the major changes between Index 2008 and 2010?

The Index 2010 features important methodological refinements that include covering more companies, more diseases, and more indicators. Other important changes are:

• Separate rankings for originator companies (20 vs. 17) and generics companies (6 vs. 3).
• Measurement of actual performance on top of commitments and transparency.
• Additional focus on non-communicable diseasesSpecific coverage of innovations in the sector.
• More diversified sources of information.